Severe short stature in cartilage-hair hypoplasia responds differently to recombinant human growth hormone even between siblings with identical genetic variants, Cureus reported.
Cartilage-hair hypoplasia is a rare autosomal recessive skeletal dysplasia linked to biallelic variants in the RMRP gene. The condition combines disproportionate short stature and sparse hair with variable immune and gastrointestinal complications.
Treating this genetic disorder with recombinant human growth hormone remains off-label and controversial due to limited clinical trial data. Medical teams evaluated a brother and sister in the United Kingdom and Portugal who share identical compound heterozygous variants in the RMRP gene.
Both children presented with severe short stature and subnormal growth hormone stimulation tests before starting treatment.
The boy experienced a clear increase in growth velocity and height standard deviation score while receiving recombinant human growth hormone.
His sister showed only a minimal and transient height response to the same therapy. Both siblings subsequently developed obesity-related metabolic changes alongside T-cell lymphopenia.
Genetic testing at the Manchester Centre for Genomic Medicine confirmed that both children inherited the same variants in trans from non-consanguineous parents. The boy demonstrated low peaks during glucagon and arginine stimulation tests, whereas his sister displayed a borderline peak during a single glucagon stimulation test.
| Clinical Feature | Patient 1 (Brother) | Patient 2 (Sister) |
|---|---|---|
| Genetic Variants | Compound heterozygous RMRP | Compound heterozygous RMRP |
| Initial Height SDS | Around −3.6 | Below −3 |
| Growth Hormone Response | Clear increase in velocity | Minimal and transient |
| Metabolic Complications | Insulin resistance / Obesity | Insulin resistance / Obesity |
| Immunological Phenotype | T-cell lymphopenia | Severe T-cell lymphopenia |
The male patient maintained part of his height standard deviation score gains even after clinicians stopped the growth hormone therapy. Conversely, the female patient gained negligible long-term benefit while experiencing more clinically pronounced T-cell lymphopenia.
Both patients developed insulin resistance and metabolic shifts associated with obesity during follow-up evaluations. These diverging trajectories demonstrate that identical genetic mutations do not guarantee uniform endocrine outcomes.
Endocrinologists face complex risk-benefit calculations when considering growth hormone therapy in metaphyseal chondrodysplasia. The underlying disease already carries elevated baseline risks for cellular immunodeficiency and non-Hodgkin lymphoma.
General safety concerns for recombinant human growth hormone include impaired glucose tolerance and intracranial hypertension. These known side effects require careful monitoring in pediatric patients who possess pre-existing skeletal and immunological vulnerabilities.
Early endocrine monitoring helps clinicians identify abnormal metabolic shifts before they compound existing skeletal dysplasia risks. Immunological surveillance remains critical because cellular immunodeficiency varies widely from mild T-cell reductions to severe combined immunodeficiency.
Gastrointestinal symptoms and anemia also require regular screening protocols during childhood development. Multidisciplinary care teams coordinate longitudinal assessments to track both metabolic health and immune function.
Current clinical evidence suggests that growth hormone therapy cannot be generalized across all patients with cartilage-hair hypoplasia. Individualized assessments guide treatment decisions when families explore off-label endocrine interventions.
Researchers emphasize that comprehensive surveillance protocols must begin early in life for all children diagnosed with metaphyseal chondrodysplasia.
Launched in 2013, the Manchester Centre for Genomic Medicine was established through a partnership between The University of Manchester and Central Manchester University Hospitals NHS Trust. The organization brings together over 250 researchers, doctors, genetic counsellors, nurses, and diagnostic scientists working across themes focused on cancer and inherited disorders.
Operating from dedicated laboratory and clinical space, the center’s genetics service sees 12,000 patients annually from across the North of England while carrying out 20,000 diagnostic tests per year. Since 2010, Manchester-based researchers associated with the initiative have discovered more than 15 genes that cause serious developmental problems in children, blindness, deafness, and inherited cancers.
Keep reading